Healthcare Services

Giant-Cell Arteritis Market Forecast 2026–2035 Highlighting Market Data Patterns and Industry Insights

April 1, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Market Size Growth Is Projected For The Giant-Cell Arteritis Market During The Forecast Period 2026–2030?

The giant-cell arteritis market has demonstrated consistent growth in recent years. It is expected to expand from $1.12 billion in 2025 to $1.18 billion in 2026, reflecting a compound annual growth rate (CAGR) of 4.9%. This historical growth can be attributed to an aging population’s growth, the continued reliance on corticosteroid therapy, improvements in rheumatology care, the expansion of hospital-based treatment, and increased disease awareness.

The market for giant-cell arteritis is projected to experience consistent expansion over the upcoming years. This market is anticipated to reach a valuation of $1.39 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 4.3%. This anticipated growth during the forecast timeframe is primarily driven by factors such as the approval of biologic drugs, advancements in immunology research, enhanced diagnostic procedures, tailored vasculitis treatments, and the proliferation of specialized clinics. Key developments expected within this period encompass a greater uptake of biologic therapies, an elevated emphasis on prompt and precise diagnosis, a wider application of corticosteroid-sparing treatments, enhanced long-term disease surveillance, and an increasing understanding of how to prevent vision loss.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17162&type=smp

Which Economic Or Industry Drivers Are Impacting The Giant-Cell Arteritis Market?

The giant-cell arteritis market is projected to expand moving forward due to a rising emphasis on personalized medicine. This medical approach entails customizing treatment to align with individual characteristics, such as genetics, lifestyle, and environment. Personalized medicine is gaining prominence because of progress in genomics, biotechnology, and data analytics, which facilitates targeted therapies that improve treatment effectiveness and minimize adverse effects for individuals. For giant-cell arteritis (GCA), personalized medicine can be beneficial by allowing for specific therapies developed from individual patient factors such as genetic predispositions, immune profiles, and disease manifestations. As an illustration, in February 2024, the Personalized Medicine Coalition (PMC), a U.S.-based non-profit organization, indicated that personalized medicines accounted for over one-third of new drug approvals by the U.S. Food and Drug Administration (FDA) for the fourth consecutive year in 2023. In that year, the FDA sanctioned 16 new personalized treatments tailored for rare diseases, representing a notable increase from six approvals in 2022. Furthermore, the approvals in 2023 included seven cancer medications and three treatments for various other diseases and conditions. Consequently, the growing emphasis on personalized medicine is driving the growth of the giant-cell arteritis market.

What Market Segments Are Evaluated Within The Giant-Cell Arteritis Market?

The giant-cell arteritis market covered in this report is segmented –

1) By Therapeutics: Prednisone, Methotrexate, Tocilizumab, Aspirin

2) By Mechanism Of Action: Corticosteroids, Immunosuppressive Agents, Anticoagulants, Other Mechanisms Of Action

3) By Route Of Administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By Prednisone: Oral Prednisone, Intravenous (IV) Prednisone, Low-Dose Prednisone Therapy, High-Dose Prednisone Therapy

2) By Methotrexate: Oral Methotrexate, Subcutaneous Methotrexate, Methotrexate Monotherapy, Methotrexate Combination Therapy

3) By Tocilizumab: Intravenous Tocilizumab, Subcutaneous Tocilizumab, Tocilizumab Monotherapy, Tocilizumab In Combination With Corticosteroids

4) By Aspirin: Low-Dose Aspirin Therapy, Aspirin For Cardiovascular Risk Management, Aspirin In Combination Therapy, Enteric-Coated Aspirin

What Trends Are Affecting The Expansion Of The Giant-Cell Arteritis Market?

Major companies operating in the giant-cell arteritis are focusing on developing new products, such as biosimilars, to expand available treatment options and address the outstanding medical needs of patients. A biosimilar is defined as a biologic drug that is highly comparable to an already approved biological product, exhibiting no clinically relevant differences regarding safety, purity, and potency. For example, in April 2024, Fresenius SE & Co. KGaA, a Germany-based healthcare company, launched Tocilizumab-aazg in the US market for the treatment of chronic autoimmune diseases. This biosimilar received approval for conditions including rheumatoid arthritis (RA), systemic juvenile idiopathic arthritis (JIA), polyarticular juvenile idiopathic arthritis (PJIA), and giant cell arteritis. Its approval was founded on data from a randomized, double-blind, single-dose, parallel phase 1 trial that compared its pharmacokinetics, safety, and immunogenicity to both US and EU reference tocilizumab across three patient groups.

Who Are The Top Market Participants Influencing The Giant-Cell Arteritis Market?

Major companies operating in the giant-cell arteritis market are Roche, AbbVie, Novartis, Pfizer, Sanofi, GlaxoSmithKline, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen, Bristol-Myers Squibb, Johnson & Johnson, UCB S.A., Kiniksa Pharmaceuticals Ltd., Teva Pharmaceutical Industries Ltd., Fresenius SE & Co KGaA, CSL Limited, Dr Reddy’s Laboratories, Tianjin Tianyao Pharmaceutical Co Ltd, Gilead Sciences Inc, Sobi AB

Read the full giant-cell arteritis market report here:

https://www.thebusinessresearchcompany.com/report/giant-cell-arteritis-global-market-report

What Are The Top-Performing Regions Within The Giant-Cell Arteritis Market?

North America was the largest region in the giant-cell arteritis market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the giant-cell arteritis market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Giant-Cell Arteritis Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=17162&type=smp

Browse Through More Reports Similar to the Global Giant-Cell Arteritis Market 2026, By The Business Research Company

Monkey Pox Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/monkey-pox-testing-global-market-report

Enteric Disease Testing Global Market Report

https://www.thebusinessresearchcompany.com/report/enteric-disease-testing-global-market-report

Bowel Management Systems Global Market Report

https://www.thebusinessresearchcompany.com/report/bowel-management-systems-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795